UA81280C2 - Ліофілізована композиція для черезлегеневого введення та її застосування (варіанти), спосіб виробництва порошкоподібного препарату для черезлегеневого введення, порошкова інгаляційна система, спосіб черезлегеневого введення - Google Patents

Ліофілізована композиція для черезлегеневого введення та її застосування (варіанти), спосіб виробництва порошкоподібного препарату для черезлегеневого введення, порошкова інгаляційна система, спосіб черезлегеневого введення Download PDF

Info

Publication number: UA81280C2
Authority: UA; Ukraine
Prior art keywords: air; lyophilized composition; transpulmonary administration; finely dispersed; inhalation
Prior art date: 2001-06-15

Application number

UAA200506798A

Other languages

English (en)

Russian (ru)

Ukrainian (uk)

Inventor

Тікамаса Ямасіта

Акіцуна Акагі

Юітіро Фукунага

Original Assignee

Оцука Фармасьютікал Ко., Лтд.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-06-15

Filing date

2003-12-12

Publication date

2007-12-25

2003-12-12 Application filed by Оцука Фармасьютікал Ко., Лтд. filed Critical Оцука Фармасьютікал Ко., Лтд.

2007-12-25 Publication of UA81280C2 publication Critical patent/UA81280C2/uk

Links

239000000203 mixture Substances 0.000 title claims abstract description 587
239000000843 powder Substances 0.000 title claims abstract description 348
238000000034 method Methods 0.000 title claims description 129
238000004519 manufacturing process Methods 0.000 title claims description 85
238000002360 preparation method Methods 0.000 title claims description 74
230000008569 process Effects 0.000 title description 5
239000002245 particle Substances 0.000 claims abstract description 300
239000010419 fine particle Substances 0.000 claims abstract description 162
238000004108 freeze drying Methods 0.000 claims abstract description 71
239000007788 liquid Substances 0.000 claims abstract description 54
239000003814 drug Substances 0.000 claims description 156
229940079593 drug Drugs 0.000 claims description 148
239000004480 active ingredient Substances 0.000 claims description 118
239000004615 ingredient Substances 0.000 claims description 57
230000000694 effects Effects 0.000 claims description 54
230000009466 transformation Effects 0.000 claims description 22
238000007789 sealing Methods 0.000 claims description 5
230000001131 transforming effect Effects 0.000 claims description 5
238000006243 chemical reaction Methods 0.000 claims description 3
238000007599 discharging Methods 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 description 47
230000002209 hydrophobic effect Effects 0.000 description 44
229940024606 amino acid Drugs 0.000 description 35
235000001014 amino acid Nutrition 0.000 description 34
150000001413 amino acids Chemical class 0.000 description 34
239000000126 substance Substances 0.000 description 33
239000000725 suspension Substances 0.000 description 30
235000018102 proteins Nutrition 0.000 description 29
102000004169 proteins and genes Human genes 0.000 description 29
108010016626 Dipeptides Proteins 0.000 description 28
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 27
108020004707 nucleic acids Proteins 0.000 description 27
102000039446 nucleic acids Human genes 0.000 description 27
150000007523 nucleic acids Chemical class 0.000 description 27
210000004072 lung Anatomy 0.000 description 25
239000000243 solution Substances 0.000 description 22
239000002904 solvent Substances 0.000 description 19
239000000969 carrier Substances 0.000 description 16
108090000765 processed proteins & peptides Proteins 0.000 description 16
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
239000012528 membrane Substances 0.000 description 15
239000007864 aqueous solution Substances 0.000 description 14
102000004877 Insulin Human genes 0.000 description 13
108090001061 Insulin Proteins 0.000 description 13
230000000052 comparative effect Effects 0.000 description 13
239000000412 dendrimer Substances 0.000 description 13
229920000736 dendritic polymer Polymers 0.000 description 13
229940125396 insulin Drugs 0.000 description 13
150000001720 carbohydrates Chemical class 0.000 description 12
150000003839 salts Chemical class 0.000 description 12
-1 for example Proteins 0.000 description 11
238000003780 insertion Methods 0.000 description 11
230000037431 insertion Effects 0.000 description 11
239000002502 liposome Substances 0.000 description 11
230000029058 respiratory gaseous exchange Effects 0.000 description 11
238000001694 spray drying Methods 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
238000009826 distribution Methods 0.000 description 10
239000002609 medium Substances 0.000 description 10
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
102000004196 processed proteins & peptides Human genes 0.000 description 9
108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
239000013543 active substance Substances 0.000 description 8
238000002296 dynamic light scattering Methods 0.000 description 8
238000000227 grinding Methods 0.000 description 8
150000001408 amides Chemical class 0.000 description 7
238000011049 filling Methods 0.000 description 7
238000005259 measurement Methods 0.000 description 7
101000976075 Homo sapiens Insulin Proteins 0.000 description 6
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 6
239000003125 aqueous solvent Substances 0.000 description 6
239000013078 crystal Substances 0.000 description 6
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 6
229940126601 medicinal product Drugs 0.000 description 6
230000002093 peripheral effect Effects 0.000 description 6
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 6
239000004474 valine Substances 0.000 description 6
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
239000002585 base Substances 0.000 description 5
229940119744 dextran 40 Drugs 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 5
150000002632 lipids Chemical class 0.000 description 5
235000015097 nutrients Nutrition 0.000 description 5
210000002345 respiratory system Anatomy 0.000 description 5
230000001133 acceleration Effects 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
238000011109 contamination Methods 0.000 description 4
239000000463 material Substances 0.000 description 4
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
230000003287 optical effect Effects 0.000 description 4
239000013612 plasmid Substances 0.000 description 4
229920001184 polypeptide Polymers 0.000 description 4
238000012545 processing Methods 0.000 description 4
230000001681 protective effect Effects 0.000 description 4
230000002685 pulmonary effect Effects 0.000 description 4
239000008213 purified water Substances 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
239000007787 solid Substances 0.000 description 4
239000004094 surface-active agent Substances 0.000 description 4
238000012546 transfer Methods 0.000 description 4
229960005486 vaccine Drugs 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
239000004475 Arginine Substances 0.000 description 3
229920000858 Cyclodextrin Polymers 0.000 description 3
201000003883 Cystic fibrosis Diseases 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
102000003745 Hepatocyte Growth Factor Human genes 0.000 description 3
108090000100 Hepatocyte Growth Factor Proteins 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
230000009471 action Effects 0.000 description 3
230000002776 aggregation Effects 0.000 description 3
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
229960003121 arginine Drugs 0.000 description 3
235000009697 arginine Nutrition 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
210000000621 bronchi Anatomy 0.000 description 3
238000004364 calculation method Methods 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
125000002091 cationic group Chemical group 0.000 description 3
230000009849 deactivation Effects 0.000 description 3
238000013461 design Methods 0.000 description 3
238000001035 drying Methods 0.000 description 3
238000002338 electrophoretic light scattering Methods 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
230000003993 interaction Effects 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000000693 micelle Substances 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
238000000926 separation method Methods 0.000 description 3
230000002269 spontaneous effect Effects 0.000 description 3
210000003437 trachea Anatomy 0.000 description 3
102000003390 tumor necrosis factor Human genes 0.000 description 3
102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
102000003951 Erythropoietin Human genes 0.000 description 2
108090000394 Erythropoietin Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
102000014150 Interferons Human genes 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 2
101100000209 Mus musculus Orm3 gene Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
102000036693 Thrombopoietin Human genes 0.000 description 2
108010041111 Thrombopoietin Proteins 0.000 description 2
239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 2
102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 2
101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 2
102000009618 Transforming Growth Factors Human genes 0.000 description 2
108010009583 Transforming Growth Factors Proteins 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
238000005054 agglomeration Methods 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
229960003589 arginine hydrochloride Drugs 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
229940097362 cyclodextrins Drugs 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
229940105423 erythropoietin Drugs 0.000 description 2
239000000945 filler Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
238000001476 gene delivery Methods 0.000 description 2
238000001415 gene therapy Methods 0.000 description 2
239000011521 glass Substances 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
239000012535 impurity Substances 0.000 description 2
230000002452 interceptive effect Effects 0.000 description 2
229940079322 interferon Drugs 0.000 description 2
229940100994 interleukin-7 Drugs 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
239000008176 lyophilized powder Substances 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
239000003094 microcapsule Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000002088 nanocapsule Substances 0.000 description 2
239000002736 nonionic surfactant Substances 0.000 description 2
108700025694 p53 Genes Proteins 0.000 description 2
230000035515 penetration Effects 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
238000003860 storage Methods 0.000 description 2
150000005846 sugar alcohols Chemical class 0.000 description 2
XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
229940034199 thyrotropin-releasing hormone Drugs 0.000 description 2
239000013598 vector Substances 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
101710081722 Antitrypsin Proteins 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
102100032528 C-type lectin domain family 11 member A Human genes 0.000 description 1
101710167766 C-type lectin domain family 11 member A Proteins 0.000 description 1
102000055006 Calcitonin Human genes 0.000 description 1
108060001064 Calcitonin Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
102000016911 Deoxyribonucleases Human genes 0.000 description 1
108010053770 Deoxyribonucleases Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102400001368 Epidermal growth factor Human genes 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
108700012941 GNRH1 Proteins 0.000 description 1
102400000321 Glucagon Human genes 0.000 description 1
108060003199 Glucagon Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
102000002265 Human Growth Hormone Human genes 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
102000014429 Insulin-like growth factor Human genes 0.000 description 1
229940118432 Interleukin receptor antagonist Drugs 0.000 description 1
102000000589 Interleukin-1 Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
102000019223 Interleukin-1 receptor Human genes 0.000 description 1
108050006617 Interleukin-1 receptor Proteins 0.000 description 1
108010017550 Interleukin-10 Receptors Proteins 0.000 description 1
102000004551 Interleukin-10 Receptors Human genes 0.000 description 1
108010017537 Interleukin-18 Receptors Proteins 0.000 description 1
102000004557 Interleukin-18 Receptors Human genes 0.000 description 1
108010038484 Interleukin-5 Receptors Proteins 0.000 description 1
102000010786 Interleukin-5 Receptors Human genes 0.000 description 1
108010038414 Interleukin-9 Receptors Proteins 0.000 description 1
102000010682 Interleukin-9 Receptors Human genes 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
241000713666 Lentivirus Species 0.000 description 1
DNDWZFHLZVYOGF-KKUMJFAQSA-N Leu-Leu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O DNDWZFHLZVYOGF-KKUMJFAQSA-N 0.000 description 1
VUZMPNMNJBGOKE-IHRRRGAJSA-N Leu-Leu-Val Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O VUZMPNMNJBGOKE-IHRRRGAJSA-N 0.000 description 1
MDSUKZSLOATHMH-UHFFFAOYSA-N Leucyl-Valine Chemical compound CC(C)CC(N)C(=O)NC(C(C)C)C(O)=O MDSUKZSLOATHMH-UHFFFAOYSA-N 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
108020001621 Natriuretic Peptide Proteins 0.000 description 1
102000004571 Natriuretic peptide Human genes 0.000 description 1
102400000050 Oxytocin Human genes 0.000 description 1
101800000989 Oxytocin Proteins 0.000 description 1
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
108090000445 Parathyroid hormone Proteins 0.000 description 1
102000003982 Parathyroid hormone Human genes 0.000 description 1
JWBLQDDHSDGEGR-DRZSPHRISA-N Phe-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 JWBLQDDHSDGEGR-DRZSPHRISA-N 0.000 description 1
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
102000003946 Prolactin Human genes 0.000 description 1
108010057464 Prolactin Proteins 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
229920001218 Pullulan Polymers 0.000 description 1
239000004373 Pullulan Substances 0.000 description 1
241000702670 Rotavirus Species 0.000 description 1
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
239000003568 Sodium, potassium and calcium salts of fatty acids Substances 0.000 description 1
101710142969 Somatoliberin Proteins 0.000 description 1
102100022831 Somatoliberin Human genes 0.000 description 1
102000005157 Somatostatin Human genes 0.000 description 1
108010056088 Somatostatin Proteins 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
102000019197 Superoxide Dismutase Human genes 0.000 description 1
108010012715 Superoxide dismutase Proteins 0.000 description 1
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
108010004977 Vasopressins Proteins 0.000 description 1
102000002852 Vasopressins Human genes 0.000 description 1
241000700605 Viruses Species 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
150000003862 amino acid derivatives Chemical class 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000003945 anionic surfactant Substances 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
230000001475 anti-trypsic effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229960004046 apomorphine Drugs 0.000 description 1
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
229940092705 beclomethasone Drugs 0.000 description 1
NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
229960002537 betamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
229940019700 blood coagulation factors Drugs 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
229960004436 budesonide Drugs 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
229960001889 buprenorphine hydrochloride Drugs 0.000 description 1
UAIXRPCCYXNJMQ-RZIPZOSSSA-N buprenorphine hydrochlorie Chemical compound [Cl-].C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)C[NH+]2CC1CC1 UAIXRPCCYXNJMQ-RZIPZOSSSA-N 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000003093 cationic surfactant Substances 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000011363 dried mixture Substances 0.000 description 1
230000009881 electrostatic interaction Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229940126864 fibroblast growth factor Drugs 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
229960002714 fluticasone Drugs 0.000 description 1
MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
229940028334 follicle stimulating hormone Drugs 0.000 description 1
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
229960004666 glucagon Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229960003971 influenza vaccine Drugs 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000009434 installation Methods 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
108010093036 interleukin receptors Proteins 0.000 description 1
102000002467 interleukin receptors Human genes 0.000 description 1
229940076144 interleukin-10 Drugs 0.000 description 1
108010052754 interleukin-14 receptor Proteins 0.000 description 1
229940100602 interleukin-5 Drugs 0.000 description 1
229940096397 interleukin-8 Drugs 0.000 description 1
229940118526 interleukin-9 Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
238000010902 jet-milling Methods 0.000 description 1
210000000867 larynx Anatomy 0.000 description 1
108010049589 leucyl-leucyl-leucine Proteins 0.000 description 1
KFKWRHQBZQICHA-UHFFFAOYSA-N leucyl-phenylalanine Chemical compound CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 KFKWRHQBZQICHA-UHFFFAOYSA-N 0.000 description 1
108010044056 leucyl-phenylalanine Proteins 0.000 description 1
239000003446 ligand Substances 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
238000012792 lyophilization process Methods 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
229960001664 mometasone Drugs 0.000 description 1
QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
239000002077 nanosphere Substances 0.000 description 1
239000000692 natriuretic peptide Substances 0.000 description 1
210000004126 nerve fiber Anatomy 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
229960001723 oxytocin Drugs 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
239000000199 parathyroid hormone Substances 0.000 description 1
229960001319 parathyroid hormone Drugs 0.000 description 1
210000003800 pharynx Anatomy 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920000098 polyolefin Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
238000003825 pressing Methods 0.000 description 1
FKNXQNWAXFXVNW-BLLLJJGKSA-N procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 description 1
229960002288 procaterol Drugs 0.000 description 1
239000000047 product Substances 0.000 description 1
229940097325 prolactin Drugs 0.000 description 1
235000013930 proline Nutrition 0.000 description 1
235000019423 pullulan Nutrition 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
230000001718 repressive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
229960002052 salbutamol Drugs 0.000 description 1
229960004017 salmeterol Drugs 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000013875 sodium salts of fatty acid Nutrition 0.000 description 1
FIWQZURFGYXCEO-UHFFFAOYSA-M sodium;decanoate Chemical compound [Na+].CCCCCCCCCC([O-])=O FIWQZURFGYXCEO-UHFFFAOYSA-M 0.000 description 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
229960000553 somatostatin Drugs 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229960001967 tacrolimus Drugs 0.000 description 1
229960003080 taurine Drugs 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
229960000187 tissue plasminogen activator Drugs 0.000 description 1
229960000707 tobramycin Drugs 0.000 description 1
NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
229960005294 triamcinolone Drugs 0.000 description 1
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
229960002109 tuberculosis vaccine Drugs 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
229960003726 vasopressin Drugs 0.000 description 1
239000013603 viral vector Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/001—Particle size control
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A61M15/0033—Details of the piercing or cutting means
- A61M15/0035—Piercing means
- A61M15/0036—Piercing means hollow piercing means
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A61M15/0033—Details of the piercing or cutting means
- A61M15/004—Details of the piercing or cutting means with fixed piercing or cutting means
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/07—General characteristics of the apparatus having air pumping means
- A61M2205/071—General characteristics of the apparatus having air pumping means hand operated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/07—General characteristics of the apparatus having air pumping means
- A61M2205/071—General characteristics of the apparatus having air pumping means hand operated
- A61M2205/075—Bulb type

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Anesthesiology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Otolaryngology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Medicinal Preparation (AREA)
Medical Preparation Storing Or Oral Administration Devices (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

UAA200506798A 2001-06-15 2003-12-12 Ліофілізована композиція для черезлегеневого введення та її застосування (варіанти), спосіб виробництва порошкоподібного препарату для черезлегеневого введення, порошкова інгаляційна система, спосіб черезлегеневого введення UA81280C2 (uk)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
JP2001182504		2001-06-15
JP2001400871		2001-12-28
JP2002111131		2002-04-12
JP2002363158		2002-12-13
PCT/JP2003/015931 WO2004054555A1 (fr)	2001-06-15	2003-12-12	Nouveau systeme d'inhalation a poudre seche pour administration transpulmonaire

Publications (1)

Publication Number	Publication Date
UA81280C2 true UA81280C2 (uk)	2007-12-25

Family

ID=32931499

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200506798A UA81280C2 (uk)	2001-06-15	2003-12-12	Ліофілізована композиція для черезлегеневого введення та її застосування (варіанти), спосіб виробництва порошкоподібного препарату для черезлегеневого введення, порошкова інгаляційна система, спосіб черезлегеневого введення

Country Status (32)

Country	Link
US (4)	US7448379B2 (fr)
EP (4)	EP1688134A3 (fr)
JP (1)	JP3635353B2 (fr)
KR (3)	KR100906754B1 (fr)
CN (2)	CN100427077C (fr)
AP (1)	AP1861A (fr)
AT (1)	ATE336989T1 (fr)
AU (3)	AU2002311213B2 (fr)
BG (1)	BG108517A (fr)
BR (2)	BR0210425B1 (fr)
CA (2)	CA2449954C (fr)
CY (1)	CY1105755T1 (fr)
CZ (1)	CZ200470A3 (fr)
DE (1)	DE60214184T2 (fr)
DK (1)	DK1402913T3 (fr)
EA (1)	EA005025B1 (fr)
EE (1)	EE04956B1 (fr)
EG (2)	EG24184A (fr)
ES (1)	ES2271266T3 (fr)
HR (2)	HRP20040033B8 (fr)
HU (1)	HU227300B1 (fr)
IL (1)	IL159080A0 (fr)
MA (1)	MA27131A1 (fr)
MX (1)	MXPA05006322A (fr)
NO (2)	NO334652B1 (fr)
NZ (2)	NZ530044A (fr)
PL (2)	PL205104B1 (fr)
PT (1)	PT1402913E (fr)
SI (1)	SI1402913T1 (fr)
TW (1)	TW570819B (fr)
UA (1)	UA81280C2 (fr)
WO (2)	WO2002102445A1 (fr)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9006175B2 (en)	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
EG24184A (en) *	2001-06-15	2008-10-08	Otsuka Pharma Co Ltd	Dry powder inhalation system for transpulmonary
GB2380410B (en) *	2001-10-05	2003-11-19	Alchemy Healthcare Ltd	Apparatus for the nasal or oral delivery of a medicament
ES2425392T3 (es)	2002-03-20	2013-10-15	Mannkind Corporation	Cartucho para un aparato de inhalación
USD514698S1 (en) *	2002-10-07	2006-02-07	Cadila Healthcare Limited	Inhalation device for the delivery and storage of powdered medicaments
CN1726045A (zh) *	2002-12-13	2006-01-25	大塚制药株式会社	经肺给药用冻干干扰素－γ组合物及其吸入系统
PL208288B1 (pl) *	2002-12-13	2011-04-29	Otsuka Pharma Co Ltd	Inhalator do przezpłucnego podawania leku
US20040187866A1 (en) *	2003-03-31	2004-09-30	Nathaniel Hughes	Liquid medicament delivery system
GB0313604D0 (en) *	2003-06-12	2003-07-16	Britannia Pharmaceuticals Ltd	Delivery device for powdered medicament
JP5183068B2 (ja) *	2003-12-22	2013-04-17	フィンレイ，ウォーレン，エイチ	大気噴出凍結乾燥法による粉末形成
EP1593376A1 (fr) *	2004-05-04	2005-11-09	Warner-Lambert Company LLC	Gélules de pullulane ameliorées
US20060021613A1 (en) *	2004-08-02	2006-02-02	Robert Overlander	Accessory for nebulizer inhaler system
DK1786784T3 (da)	2004-08-20	2011-02-14	Mannkind Corp	Katalyse af diketopiperazinsyntese
BR122019022692B1 (pt)	2004-08-23	2023-01-10	Mannkind Corporation	Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo
KR101338969B1 (ko) *	2004-11-10	2013-12-10	씨아이피엘에이 엘티디.	흡입기
FR2877925B1 (fr) *	2004-11-16	2008-09-19	Valois Sas	Dispositif de distribution de produit fluide.
DE102005016230A1 (de) *	2005-04-08	2006-10-19	Altana Pharma Ag	Vorrichtung zur Trockenvernebelung
WO2007007110A1 (fr) *	2005-07-13	2007-01-18	Cipla Limited	Dispositif inhalateur
DE102005038619A1 (de) *	2005-08-16	2007-02-22	Pari GmbH Spezialisten für effektive Inhalation	Inhalationstherapievorrichtung mit einer Ampulle für die Bevorratung eines zu vernebelnden Medikaments
WO2007033372A2 (fr)	2005-09-14	2007-03-22	Mannkind Corporation	Procede de preparation de medicaments fonde sur l'accroissement de l'affinite des surfaces de microparticules cristallines pour des principes actifs
KR100777249B1 (ko) *	2006-02-14	2007-11-28	(주)바이오니아	건조 올리고뉴클레오티드 조성물 및 이의 제조 방법
DK1986679T3 (da)	2006-02-22	2017-11-20	Mannkind Corp	Fremgangsmåde til forbedring af mikropartiklers farmaceutiske egenskaber omfattende diketopiperazin og et aktivt indholdsstof
DE102006010089A1 (de) *	2006-02-24	2007-10-18	Aha-Kunststofftechnik Gmbh	Trockenpulver-Inhalator
EP1993645A4 (fr) *	2006-03-03	2011-05-18	Stc Unm	Inhalateur a poudre seche avec mecanisme de dispersion aeroelastique
US7832399B2 (en) *	2006-03-10	2010-11-16	One Dose, Llc	Medication inhaler
US8360057B2 (en) *	2006-03-10	2013-01-29	Dose One, Llc	Medication inhaler for dispensing multiple capsules
JP2009543658A (ja) *	2006-07-14	2009-12-10	アストラゼネカ・アクチエボラーグ	乾燥粉末状の薬を投与するための吸入装置及び配送装置
DE102006047668B3 (de) *	2006-09-28	2008-04-24	Ing. Erich Pfeiffer Gmbh	Inhalationsvorrichtung
JP5388842B2 (ja) *	2007-03-09	2014-01-15	大塚製薬株式会社	インフルエンザワクチン含有凍結乾燥製剤、及びその製造方法
WO2009079078A1 (fr)	2007-12-14	2009-06-25	Labogroup S.A.S.	Administration de produits alimentaires sous forme d'aérosols
BRPI0821648A2 (pt) *	2007-12-20	2015-06-16	Astrazeneca Ab	Método e dispositivo para pó desagregante
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
USD605752S1 (en)	2008-06-13	2009-12-08	Mannkind Corporation	Dry powder inhaler
USD635241S1 (en)	2008-06-13	2011-03-29	Mannkind Corporation	Dry powder inhaler
CA3153292A1 (fr)	2008-06-13	2009-12-17	Mannkind Corporation	Inhalateur de poudre seche et systeme d'administration de medicament
CN102065942B (zh)	2008-06-20	2013-12-11	曼金德公司	用于对吸入工作进行实时描绘的交互式设备和方法
TWI532497B (zh)	2008-08-11	2016-05-11	曼凱公司	超快起作用胰島素之用途
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
EP2403490B1 (fr) *	2009-03-04	2019-08-07	MannKind Corporation	Système amélioré pour la délivrance d'un médicament sous la forme d'une poudre sèche
PL2405963T3 (pl)	2009-03-11	2014-04-30	Mannkind Corp	Urządzenie, układ i sposób pomiaru oporu inhalatora
CN101884593B (zh) *	2009-05-14	2013-09-18	许清萍	由高剂量冻干制剂调配液态制剂的方法
US8118777B2 (en) *	2009-05-29	2012-02-21	Cook Medical Technologies Llc	Systems and methods for delivering therapeutic agents
KR20180036807A (ko)	2009-06-12	2018-04-09	맨카인드 코포레이션	한정된 비표면적을 갖는 디케토피페라진 마이크로입자
AU2010266754B2 (en)	2009-07-01	2013-12-05	Astrazeneca Ab	Dispenser and method for entraining powder in an airflow
CA2778698A1 (fr)	2009-11-03	2011-05-12	Mannkind Corporation	Appareil et methode de simulation d'efforts d'inhalation
CA2779488A1 (fr)	2009-11-12	2011-05-19	Stc.Unm	Inhalateur pour poudre seche avec un element de dispersion par flottement
CN102655855B (zh) *	2009-12-14	2015-03-11	奇斯药制品公司	用于吸入的抗生素微粒
RU2571331C1 (ru)	2010-06-21	2015-12-20	Маннкайнд Корпорейшн	Системы и способы доставки сухих порошковых лекарств
EP2648788B1 (fr)	2010-12-07	2017-08-09	Respira Therapeutics, Inc.	Inhalateur de poudre sèche
KR101940832B1 (ko)	2011-04-01	2019-01-21	맨카인드 코포레이션	의약 카트리지용 블리스터 패키지
WO2012174472A1 (fr)	2011-06-17	2012-12-20	Mannkind Corporation	Microparticules de dicétopipérazine de capacité élevée
LT2739268T (lt)	2011-08-01	2019-03-25	Monash University	Inhaliacijos būdas ir kompozicija
EP2776053A1 (fr)	2011-10-24	2014-09-17	MannKind Corporation	Procédés et compositions pour traiter la douleur
US10463815B2 (en)	2012-02-21	2019-11-05	Respira Therapeutics, Inc.	Inhaler to deliver substances for prophylaxis or prevention of disease or injury caused by the inhalation of biological or chemical agents
DE102012103000A1 (de) *	2012-04-05	2013-10-10	Rpc Formatec Gmbh	Spender zur Ausbringung einer insbesondere körnigen oder pulverförmigen Substanz und Verfahren zur Entleerung einer Substanz-Aufnahme
CN104619369B (zh)	2012-07-12	2018-01-30	曼金德公司	干粉药物输送系统和方法
EP2708219A1 (fr)	2012-09-12	2014-03-19	PARI Pharma GmbH	Élément d'ouverture pour ouvrir une ampoule dans un dispositif de génération d'aérosol et dispositif de génération d'aérosol comprenant l'élément d'ouverture
EP2911690A1 (fr)	2012-10-26	2015-09-02	MannKind Corporation	Compositions et procédés de vaccin antigrippal inhalable
EP2928315A2 (fr) *	2012-12-06	2015-10-14	AeroDesigns, Inc	Distributeur d'aérosol avec cartouche comestible
CN103110611A (zh) *	2012-12-11	2013-05-22	苏州惠仁生物科技有限公司	吸入剂及其制备方法与普鲁兰糖作为吸入剂载体的应用
AU2014228415B2 (en)	2013-03-15	2018-08-09	Mannkind Corporation	Microcrystalline diketopiperazine compositions and methods
CA2918369C (fr)	2013-07-18	2021-06-29	Mannkind Corporation	Compositions pharmaceutiques en poudre seche stables a la chaleur et procedes
WO2015021064A1 (fr)	2013-08-05	2015-02-12	Mannkind Corporation	Appareil d'insufflation et procédés
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
DE102014215064A1 (de)	2014-07-31	2016-02-04	Pari GmbH Spezialisten für effektive Inhalation	Vernebler
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
DK3212212T3 (da)	2014-10-31	2020-12-21	Univ Monash	Pulverformulering
EP3244952A4 (fr)	2015-01-14	2018-11-14	Respira Therapeutics, Inc.	Procédés et dispositifs de dispersion de poudre
WO2016193956A1 (fr) *	2015-06-04	2016-12-08	Lameplast S.P.A.	Dispositif pour la distribution par pulvérisation d'un produit liquide
KR20180050320A (ko) *	2015-09-09	2018-05-14	노파르티스 아게	분무-건조된 제제의 폐로의 표적화된 전달
CN105616390B (zh) *	2016-03-24	2019-07-23	李浩莹	普鲁兰多糖及衍生物在制备缓控释放药物颗粒中的应用
JP2019519489A (ja)	2016-05-05	2019-07-11	リクイディア・テクノロジーズ・インコーポレーテッド	肺高血圧症を治療するための乾燥粉末トレプロスチニル
PH12019501134B1 (en) *	2016-12-05	2024-02-02	Microbase Technology Corp	Aerosol generating apparatus with replaceable parts
EP3559016A1 (fr) *	2016-12-23	2019-10-30	University of Copenhagen	Forme co-amorphe d'une substance et d'un dipeptide
ES2684403B1 (es) *	2017-03-31	2019-07-09	Farm Rovi Lab Sa	Procedimiento para el llenado gravimetrico en condiciones esteriles de solidos en un contenedor farmaceutico y contenedor farmaceutico utilizable en el mismo
US11426543B2 (en) *	2017-04-18	2022-08-30	Inspiring Pty Ltd	Dry powder inhaler and flexible bag spacer device for a dry powder inhaler
US10252283B2 (en) *	2017-07-17	2019-04-09	Yoanna Gouchtchina	Dermal spray apparatus and method
JP7254074B2 (ja) *	2017-11-02	2023-04-07	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	液滴分注デバイスおよびシステム
JP6489669B1 (ja) *	2018-10-30	2019-03-27	ルアン株式会社	スクイズ容器
CN109954200A (zh) *	2019-04-16	2019-07-02	郑州大学第一附属医院	一种呼吸内科护理用给药装置
WO2020217107A1 (fr) *	2019-04-25	2020-10-29	Agco Corporation	Appareil et procédés pour mesurer des états de sol
CN112237668A (zh) *	2019-07-17	2021-01-19	杭州亿脑创新工场有限公司	多剂量粉末药物给药装置及适用于该装置的药联
US11944178B2 (en)	2020-04-07	2024-04-02	Kozhya LLC SP Z.O.O.	Dermal spray apparatus and method
WO2021211624A1 (fr) *	2020-04-14	2021-10-21	Qool Therapeutics, Inc.	Générateur de particules congelées utilisant un micro-distributeur de liquide
US20220184325A1 (en) *	2020-12-15	2022-06-16	Sanara Medtech Inc.	Powder applicator
TWI763510B (zh) *	2021-05-28	2022-05-01	林錫璋	藥粉輸送裝置
US12376665B2 (en)	2021-10-14	2025-08-05	Kozhya LLC Sp. z o.o.	Dermal spray apparatus with disposable cartrdige and method
USD1033635S1 (en)	2022-05-09	2024-07-02	Quantum Skin SP Z O.O	Dermal spray nozzle
USD1035867S1 (en)	2022-05-09	2024-07-16	Kozhya LLC Sp. z o.o.	Dermal spray apparatus
USD1046122S1 (en)	2022-05-09	2024-10-08	Quantum Skin Limited Liability Company	Dermal spray cartridge
USD1038383S1 (en)	2022-05-09	2024-08-06	Kozhya LLC Sp. z o.o.	Dermal spray apparatus
CN116350607A (zh) *	2023-04-11	2023-06-30	胡崇茂	一种干细胞吸入组合物及其制备方法和应用
WO2025225923A1 (fr) *	2024-04-25	2025-10-30	주식회사 리센스메디컬	Dispositif de pulvérisation de composition et système de pulvérisation le comprenant

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1950926A (en) *	1932-10-05	1934-03-13	Lobl Frederick	Nasal inhaler
GB1479283A (en) *	1973-07-23	1977-07-13	Bespak Industries Ltd	Inhaler for powdered medicament
US3874381A (en) *	1974-05-28	1975-04-01	Smithkline Corp	Dual nozzle intranasal delivery device
GB1521000A (en) *	1975-06-13	1978-08-09	Syntex Puerto Rico Inc	Inhalation device
JPS58152498A (ja)	1982-03-06	1983-09-10	Terumo Corp	低分子ペプチド混合物の製造方法
WO1984002274A1 (fr)	1982-12-09	1984-06-21	Hafsten Raymond J Jr	Enzymes stabilisees et activees utilisees pour guerir des blessures
EP0133767B1 (fr)	1983-08-04	1991-04-03	The Green Cross Corporation	Composition de gamma interféron
JPS6052847A (ja)	1983-09-01	1985-03-26	Konishiroku Photo Ind Co Ltd	ハロゲン化銀感光材料の現像処理方法
EP0168008A3 (fr)	1984-07-10	1986-12-30	Takeda Chemical Industries, Ltd.	Composition stable d'interféron-gamma
DE3729863A1 (de)	1987-09-05	1989-03-16	Boehringer Mannheim Gmbh	Stabilisierte erythropoietin-lyophilisate
JPH01116045A (ja) *	1987-10-29	1989-05-09	Toshiba Corp	耐食性ジルコニウム合金
EP0360340A1 (fr)	1988-09-19	1990-03-28	Akzo N.V.	Composition pour administration par voie nasale contenant un peptide
JPH07116022B2 (ja)	1989-04-18	1995-12-13	三共株式会社	凍結乾燥製剤の製法
DK0407028T4 (da) *	1989-05-31	2000-01-31	Fisons Plc	Anordning til inhalation af medikamenter og sammensætning af medikamenter
FR2649323B1 (fr)	1989-07-04	1995-06-30	Valois	Dispositif de projection et de pulverisation d'une dose d'un produit divisable
JPH0341033A (ja)	1989-07-07	1991-02-21	Kyowa Hakko Kogyo Co Ltd	安定なモチリン類含有製剤
DK544589D0 (da) *	1989-11-01	1989-11-01	Novo Nordisk As	Manuel betjent apparat til dispensering af en forudbestemt maengde af et pulverformet stof
KR910014122A (ko)	1990-01-19	1991-08-31	디께다 가즈히꼬	에토포시드-2-디메틸아미노 화합물의 동결건조 제제
JPH05963A (ja)	1990-04-13	1993-01-08	Toray Ind Inc	ポリペプチド類組成物
JPH0464878A (ja) *	1990-07-04	1992-02-28	Mitsubishi Heavy Ind Ltd	吸収冷凍機の吸収器
GB9027234D0 (en)	1990-12-15	1991-02-06	Harris Pharma Ltd	An inhalation device
DE69232374T2 (de)	1991-04-08	2002-08-29	Koken Co. Ltd., Tokyo	Poröse feste zubereitung, die eine physiologische aktive proteinverbindung enthält
JP3131271B2 (ja)	1992-03-24	2001-01-31	住友ゴム工業株式会社	防振支承
US6582728B1 (en)	1992-07-08	2003-06-24	Inhale Therapeutic Systems, Inc.	Spray drying of macromolecules to produce inhaleable dry powders
US5785049A (en) *	1994-09-21	1998-07-28	Inhale Therapeutic Systems	Method and apparatus for dispersion of dry powder medicaments
JPH06186141A (ja) *	1992-12-16	1994-07-08	Hitachi Ltd	残留応力予測法
PL173090B1 (pl) *	1992-12-18	1998-01-30	Schering Corp	Inhalator do sproszkowanych lekarstw
JPH0652847U (ja)	1992-12-28	1994-07-19	セントラル自動車株式会社	防火シャッター付き搬送装置
US5354934A (en) *	1993-02-04	1994-10-11	Amgen Inc.	Pulmonary administration of erythropoietin
JP3007785B2 (ja)	1993-03-16	2000-02-07	旭化成工業株式会社	トロンボモジュリン組成物およびその変性防止方法
US5533502A (en) *	1993-05-28	1996-07-09	Vortran Medical Technology, Inc.	Powder inhaler with aerosolization occurring within each individual powder receptacle
WO1994028876A1 (fr)	1993-06-07	1994-12-22	Advanced Therapies, Inc.	Poudres de liposomes
US5349947A (en) *	1993-07-15	1994-09-27	Newhouse Michael T	Dry powder inhaler and process that explosively discharges a dose of powder and gas from a soft plastic pillow
ATE299892T1 (de)	1994-05-18	2005-08-15	Nektar Therapeutics	Methoden und zusammensetzungen für die trockenpuderarznei aus interferonen
ES2302332T3 (es) *	1994-09-21	2008-07-01	Nektar Therapeutics	Aparato y metodos para dispersar medicamentos en polvo seco.
US6117455A (en)	1994-09-30	2000-09-12	Takeda Chemical Industries, Ltd.	Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
JPH08103499A (ja) *	1994-10-04	1996-04-23	Unisia Jecs Corp	吸入式投薬器
GB9501841D0 (en)	1995-01-31	1995-03-22	Co Ordinated Drug Dev	Improvements in and relating to carrier particles for use in dry powder inhalers
US5654007A (en) *	1995-06-07	1997-08-05	Inhale Therapeutic Systems	Methods and system for processing dispersible fine powders
JP3317823B2 (ja) *	1995-08-11	2002-08-26	株式会社ユニシアジェックス	投薬器
DE19536902A1 (de)	1995-10-04	1997-04-10	Boehringer Ingelheim Int	Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
JP3317827B2 (ja) *	1995-10-09	2002-08-26	株式会社ユニシアジェックス	投薬器
TW403653B (en) *	1995-12-25	2000-09-01	Otsuka Pharma Co Ltd	Dry compositions
US20030138402A1 (en)	1995-12-25	2003-07-24	Otsuka Pharmaceutical Co., Ltd.	Dry compositions
JP3328132B2 (ja) *	1996-03-21	2002-09-24	株式会社ユニシアジェックス	吸入式投薬器
US5875776A (en) *	1996-04-09	1999-03-02	Vivorx Pharmaceuticals, Inc.	Dry powder inhaler
US5826633A (en)	1996-04-26	1998-10-27	Inhale Therapeutic Systems	Powder filling systems, apparatus and methods
AUPN976496A0 (en) *	1996-05-10	1996-05-30	Glaxo Wellcome Australia Ltd	Unit dose dispensing device
US5663492A (en) *	1996-06-05	1997-09-02	Alapati; Rama Rao	System for continuous analysis and modification of characteristics of a liquid hydrocarbon stream
DK1014943T3 (da) *	1997-02-05	2002-10-14	Jago Res Ag	Medicinske aerosolformuleringer
DE19704849B4 (de) *	1997-02-08	2011-02-17	Ing. Erich Pfeiffer Gmbh	Austragvorrichtung für Medien
US6503537B2 (en) *	1997-03-20	2003-01-07	Schering Corporation	Preparation of powder agglomerates
US6394085B1 (en) *	1997-09-25	2002-05-28	Norton Healthcare Ltd.	Inhaler spacer
ATE215820T1 (de) *	1997-10-08	2002-04-15	Sepracor Inc	Dosierungsform zur verabreichung von aerosolen
NZ504021A (en) *	1997-10-17	2003-04-29	Systemic Pulmonary Delivery Lt	Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
JP4266399B2 (ja)	1997-12-04	2009-05-20	帝人株式会社	粉末状吸入用医薬品組成物
WO1999044594A1 (fr) *	1998-03-05	1999-09-10	Nippon Shinyaku Co., Ltd.	Emulsions huileuses destinees a etre administrees par inhalation
JP3547612B2 (ja) *	1998-03-20	2004-07-28	株式会社日立ユニシアオートモティブ	吸入式投薬器
US6284282B1 (en) *	1998-04-29	2001-09-04	Genentech, Inc.	Method of spray freeze drying proteins for pharmaceutical administration
MA25590A1 (fr) *	1998-09-14	2002-12-31	Inhale Therapeutic Syst	Agent actif de delivraison de poudre seche
US5952232A (en)	1998-09-17	1999-09-14	Rothman; James Edward	Expandible microparticle intracellular delivery system
US6745763B2 (en) *	1998-10-27	2004-06-08	Garth T. Webb	Vaporizing device for administering sterile medication
JP2000233023A (ja)	1999-02-15	2000-08-29	Hiroshi Matsuzawa	鼻腔内洗浄器
GB2353222B (en) *	1999-06-23	2001-09-19	Cambridge Consultants	Inhalers
GB9919693D0 (en) *	1999-08-19	1999-10-20	Rhone Poulenc Rorer Ltd	Process
JP2001151673A (ja)	1999-09-06	2001-06-05	Nikken Chem Co Ltd	吸入用粉末製剤の製造方法
IL149085A0 (en) *	1999-10-29	2002-11-10	Inhale Therapeutic Syst	A dry powder composition containing a di or tripeptide
JP4931282B2 (ja) *	2000-10-02	2012-05-16	日本ケミカルリサーチ株式会社	生理活性ペプチド含有粉末
JP3943845B2 (ja) *	2001-02-15	2007-07-11	芳枝米谷	リポソームベクター
EG24184A (en) *	2001-06-15	2008-10-08	Otsuka Pharma Co Ltd	Dry powder inhalation system for transpulmonary
PL208288B1 (pl) *	2002-12-13	2011-04-29	Otsuka Pharma Co Ltd	Inhalator do przezpłucnego podawania leku

2002
- 2002-06-12 EG EG2002060661A patent/EG24184A/xx active
- 2002-06-14 PT PT02736105T patent/PT1402913E/pt unknown
- 2002-06-14 KR KR1020077009246A patent/KR100906754B1/ko not_active Expired - Fee Related
- 2002-06-14 IL IL15908002A patent/IL159080A0/xx active IP Right Grant
- 2002-06-14 CZ CZ200470A patent/CZ200470A3/cs unknown
- 2002-06-14 EP EP06010993A patent/EP1688134A3/fr not_active Withdrawn
- 2002-06-14 DK DK02736105T patent/DK1402913T3/da active
- 2002-06-14 DE DE60214184T patent/DE60214184T2/de not_active Expired - Lifetime
- 2002-06-14 HU HU0400217A patent/HU227300B1/hu not_active IP Right Cessation
- 2002-06-14 US US10/170,339 patent/US7448379B2/en not_active Expired - Fee Related
- 2002-06-14 CA CA2449954A patent/CA2449954C/fr not_active Expired - Fee Related
- 2002-06-14 AU AU2002311213A patent/AU2002311213B2/en not_active Ceased
- 2002-06-14 EP EP06010991A patent/EP1688133A1/fr not_active Withdrawn
- 2002-06-14 NZ NZ530044A patent/NZ530044A/en not_active IP Right Cessation
- 2002-06-14 JP JP2003505028A patent/JP3635353B2/ja not_active Expired - Fee Related
- 2002-06-14 BR BRPI0210425-3A patent/BR0210425B1/pt not_active IP Right Cessation
- 2002-06-14 WO PCT/JP2002/005955 patent/WO2002102445A1/fr not_active Ceased
- 2002-06-14 EA EA200400045A patent/EA005025B1/ru not_active IP Right Cessation
- 2002-06-14 ES ES02736105T patent/ES2271266T3/es not_active Expired - Lifetime
- 2002-06-14 KR KR1020077009245A patent/KR100907333B1/ko not_active Expired - Fee Related
- 2002-06-14 CN CNB02811941XA patent/CN100427077C/zh not_active Expired - Fee Related
- 2002-06-14 TW TW091112991A patent/TW570819B/zh not_active IP Right Cessation
- 2002-06-14 PL PL367161A patent/PL205104B1/pl unknown
- 2002-06-14 EE EEP200400011A patent/EE04956B1/xx not_active IP Right Cessation
- 2002-06-14 AP APAP/P/2003/002945A patent/AP1861A/en active
- 2002-06-14 HR HR20040033A patent/HRP20040033B8/xx not_active IP Right Cessation
- 2002-06-14 AT AT02736105T patent/ATE336989T1/de active
- 2002-06-14 EP EP02736105A patent/EP1402913B1/fr not_active Expired - Lifetime
- 2002-06-14 SI SI200230430T patent/SI1402913T1/sl unknown
2003
- 2003-12-12 BR BR0316754-2A patent/BR0316754A/pt not_active Application Discontinuation
- 2003-12-12 UA UAA200506798A patent/UA81280C2/uk unknown
- 2003-12-12 US US10/538,837 patent/US7735485B2/en not_active Expired - Fee Related
- 2003-12-12 CA CA2507766A patent/CA2507766C/fr not_active Expired - Fee Related
- 2003-12-12 CN CNB2003801058762A patent/CN1323658C/zh not_active Expired - Fee Related
- 2003-12-12 WO PCT/JP2003/015931 patent/WO2004054555A1/fr not_active Ceased
- 2003-12-12 NO NO20035554A patent/NO334652B1/no not_active IP Right Cessation
- 2003-12-12 MX MXPA05006322A patent/MXPA05006322A/es active IP Right Grant
- 2003-12-12 AU AU2003289051A patent/AU2003289051B2/en not_active Ceased
- 2003-12-12 PL PL377554A patent/PL209876B1/pl unknown
- 2003-12-12 EP EP03778863A patent/EP1579855A4/fr not_active Withdrawn
- 2003-12-12 KR KR1020057010714A patent/KR101049914B1/ko not_active Expired - Fee Related
- 2003-12-12 HR HR20050639A patent/HRP20050639A2/xx not_active Application Discontinuation
- 2003-12-12 NZ NZ540935A patent/NZ540935A/en not_active IP Right Cessation
2004
- 2004-01-08 BG BG108517A patent/BG108517A/xx unknown
- 2004-01-15 MA MA27481A patent/MA27131A1/fr unknown
2005
- 2005-06-13 EG EGNA2005000290 patent/EG23775A/xx active
- 2005-07-05 NO NO20053300A patent/NO20053300L/no not_active Application Discontinuation
2006
- 2006-11-02 CY CY20061101585T patent/CY1105755T1/el unknown
2008
- 2008-02-07 AU AU2008200583A patent/AU2008200583B2/en not_active Ceased
- 2008-08-30 US US12/202,220 patent/US8443799B2/en not_active Expired - Fee Related
- 2008-10-10 US US12/202,221 patent/US8333193B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
KR100907333B1 (ko)	2009-07-13
KR101049914B1 (ko)	2011-07-15
EP1579855A4 (fr)	2009-11-04
EP1688134A2 (fr)	2006-08-09
WO2004054555A1 (fr)	2004-07-01
HRP20040033B1 (en)	2007-11-30
US7735485B2 (en)	2010-06-15
AP2003002945A0 (en)	2003-12-31
EP1579855A1 (fr)	2005-09-28
EA005025B1 (ru)	2004-10-28
PL377554A1 (pl)	2006-02-06
CA2449954C (fr)	2011-08-23
NO20053300D0 (no)	2005-07-05
AU2008200583B2 (en)	2011-05-19
EP1402913B1 (fr)	2006-08-23
CN1323658C (zh)	2007-07-04
EP1402913A4 (fr)	2004-12-01
US8443799B2 (en)	2013-05-21
BG108517A (en)	2005-02-28
CA2507766C (fr)	2011-11-01
CN1726014A (zh)	2006-01-25
KR20070050105A (ko)	2007-05-14
TW570819B (en)	2004-01-11
NZ530044A (en)	2005-09-30
US8333193B2 (en)	2012-12-18
ES2271266T3 (es)	2007-04-16
EP1688133A1 (fr)	2006-08-09
US20090126732A1 (en)	2009-05-21
EG24184A (en)	2008-10-08
CZ200470A3 (cs)	2004-07-14
CN100427077C (zh)	2008-10-22
EE200400011A (et)	2004-02-16
BR0210425A (pt)	2004-08-17
HRP20050639A2 (en)	2006-07-31
NZ540935A (en)	2007-06-29
EA200400045A1 (ru)	2004-06-24
BR0316754A (pt)	2005-10-25
ATE336989T1 (de)	2006-09-15
AU2003289051B2 (en)	2008-06-26
PL209876B1 (pl)	2011-10-31
JP3635353B2 (ja)	2005-04-06
EP1402913A1 (fr)	2004-03-31
US20060073105A1 (en)	2006-04-06
BR0210425B1 (pt)	2012-12-11
AU2002311213B2 (en)	2007-12-13
KR20070048813A (ko)	2007-05-09
CA2507766A1 (fr)	2004-07-01
EP1688134A3 (fr)	2009-11-18
US20070065371A2 (en)	2007-03-22
EE04956B1 (et)	2008-02-15
US20030101995A1 (en)	2003-06-05
DE60214184D1 (de)	2006-10-05
HUP0400217A2 (en)	2004-09-28
US7448379B2 (en)	2008-11-11
NO334652B1 (no)	2014-05-05
DK1402913T3 (da)	2006-12-11
HK1082403A1 (en)	2006-06-09
CY1105755T1 (el)	2010-12-22
MXPA05006322A (es)	2005-08-26
AU2003289051A1 (en)	2004-07-09
MA27131A1 (fr)	2005-01-03
SI1402913T1 (sl)	2007-02-28
CN1516606A (zh)	2004-07-28
JPWO2002102445A1 (ja)	2004-09-30
PL367161A1 (en)	2005-02-21
NO20035554L (no)	2004-02-12
WO2002102445A1 (fr)	2002-12-27
HRP20040033B8 (hr)	2008-09-30
NO20035554D0 (no)	2003-12-12
HRP20040033A2 (en)	2004-08-31
AU2008200583A1 (en)	2008-02-28
AP1861A (en)	2008-07-02
KR100906754B1 (ko)	2009-07-09
CA2449954A1 (fr)	2002-12-27
KR20050084272A (ko)	2005-08-26
PL205104B1 (pl)	2010-03-31
DE60214184T2 (de)	2007-06-28
EG23775A (en)	2007-08-08
NO20053300L (no)	2005-09-12
IL159080A0 (en)	2004-05-12
PT1402913E (pt)	2006-12-29
US20090095293A1 (en)	2009-04-16
HU227300B1 (en)	2011-02-28

Publication	Publication Date	Title
UA81280C2 (uk)	2007-12-25	Ліофілізована композиція для черезлегеневого введення та її застосування (варіанти), спосіб виробництва порошкоподібного препарату для черезлегеневого введення, порошкова інгаляційна система, спосіб черезлегеневого введення
Irngartinger et al.	2004	Pulmonary delivery of therapeutic peptides via dry powder inhalation: effects of micronisation and manufacturing
NO20131597L (no)	2004-02-12	Tørr-pulver inhaleringssystem for transpulmonal administrering
JP2006509825A (ja)	2006-03-23	経肺投与用インターフェロン−γ凍結乾燥組成物及びその吸入システム
JP4822709B2 (ja)	2011-11-24	新しい経肺投与用乾燥粉末吸入システム
CN101366989B (zh)	2012-03-21	经肺给药用干燥粉末吸入系统
HK1127567B (en)	2012-09-14	Dry powder inhalation system for transpulmonary administration